{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T19:54:50Z","timestamp":1784231690387,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"XenoPort, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s40263-016-0329-4","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T08:27:07Z","timestamp":1460622427000},"page":"305-316","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Effect of Gabapentin Enacarbil on Quality of Life and Mood Outcomes in a Pooled Population of Adult Patients with Moderate-to-Severe Primary Restless Legs Syndrome"],"prefix":"10.1007","volume":"30","author":[{"given":"Alon Y.","family":"Avidan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Jaros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendoline","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,11]]},"reference":[{"key":"329_CR1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1389-9457(03)00010-8","volume":"4","author":"RP Allen","year":"2003","unstructured":"Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epide-miology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4:101\u201319.","journal-title":"Sleep Med"},{"key":"329_CR2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.sleep.2004.03.006","volume":"5","author":"W Hening","year":"2004","unstructured":"Hening W, Walters AS, Allen RP, et al. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med. 2004;5:237\u201346.","journal-title":"Sleep Med"},{"key":"329_CR3","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.sleep.2013.05.016","volume":"14","author":"D Garcia-Borreguero","year":"2013","unstructured":"Garcia-Borreguero D, Kohnen R, Silber MH, et al. The long-term treatment of restless legs syndrome\/Willis-Ekbom disease: evidence based guidelines and clinical consensus best practice guidance: a report from the international restless legs syndrome study group. Sleep Med. 2013;14:675\u201384.","journal-title":"Sleep Med"},{"key":"329_CR4","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.sleep.2014.03.025","volume":"15","author":"RP Allen","year":"2014","unstructured":"Allen RP, Picchietti DL, Garcia-Borreguero D, et al. Restless legs syndrome\/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria\u2014history, rationale, description, and significance. Sleep Med. 2014;15:860\u201373.","journal-title":"Sleep Med"},{"key":"329_CR5","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/archinte.164.2.196","volume":"164","author":"K Berger","year":"2004","unstructured":"Berger K, Luedemann J, Trenkwalder C, et al. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med. 2004;164:196\u2013202.","journal-title":"Arch Intern Med"},{"key":"329_CR6","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.smrv.2011.05.002","volume":"16","author":"MM Ohayon","year":"2012","unstructured":"Ohayon MM, O\u2019Hara R, Vitiello MV. Epidemiology of restless legs syndrome: a synthesis of the literature. Sleep Med Rev. 2012;16:283\u201395.","journal-title":"Sleep Med Rev"},{"key":"329_CR7","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.sleep.2010.12.018","volume":"12","author":"KE Innes","year":"2011","unstructured":"Innes KE, Selfe TK, Agarwal P. Prevalence of restless legs syndrome in North American and Western European populations: a systematic review. Sleep Med. 2011;12:623\u201334.","journal-title":"Sleep Med"},{"key":"329_CR8","first-page":"226","volume":"75","author":"S Sevim","year":"2004","unstructured":"Sevim S, Dogu O, Kaleagasi H, Aral M, Metin O, Camdeviren H. Correlation of anxiety and depression symptoms in patients with restless legs syndrome: a population based survey. J Neurol Neurosurg Psychiatry. 2004;75:226\u201330.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"329_CR9","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/archinte.165.11.1286","volume":"165","author":"RP Allen","year":"2005","unstructured":"Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med. 2005;165:1286\u201392.","journal-title":"Arch Intern Med"},{"key":"329_CR10","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0149-2918(04)90136-1","volume":"26","author":"L Abetz","year":"2004","unstructured":"Abetz L, Allen R, Follet A, et al. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther. 2004;26:925\u201335.","journal-title":"Clin Ther"},{"key":"329_CR11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1477-7525-9-73","volume":"9","author":"H Scholz","year":"2011","unstructured":"Scholz H, Benes H, Happe S, et al. Psychological distress of patients suffering from restless legs syndrome: a cross-sectional study. Health Qual Life Outcomes. 2011;9:73.","journal-title":"Health Qual Life Outcomes."},{"key":"329_CR12","first-page":"1069","volume":"32","author":"SJ Cho","year":"2009","unstructured":"Cho SJ, Hong JP, Hahm BJ, et al. Restless legs syndrome in a community sample of Korean adults: prevalence, impact on quality of life, and association with DSM-IV psychiatric disorder. Sleep. 2009;32:1069\u201376.","journal-title":"Sleep"},{"key":"329_CR13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.17925\/ENR.2013.08.02.97","volume":"8","author":"A Kalloo","year":"2013","unstructured":"Kalloo A, Garnaldo CE, Kwan AB, et al. The impact of restless legs syndrome\/Willis-Ekbom Disorder on quality of life. Eur Neurol Rev. 2013;8:97\u2013104.","journal-title":"Eur Neurol Rev."},{"key":"329_CR14","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/mds.20257","volume":"19","author":"AS Walters","year":"2004","unstructured":"Walters AS, Ondo WG, Dreykluft T, et al. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord. 2004;19:1414\u201323.","journal-title":"Mov Disord"},{"key":"329_CR15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.sleep.2010.08.005","volume":"12","author":"P Montagna","year":"2011","unstructured":"Montagna P, Hornyak M, Ulfberg J, et al. Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood. Sleep Med. 2011;12:34\u201340.","journal-title":"Sleep Med"},{"key":"329_CR16","first-page":"CD006009","volume":"16","author":"H Scholz","year":"2011","unstructured":"Scholz H, Trenkwalder C, Kohnen R, et al. Dopamine agonists for restless legs syndrome. Cochrane Database Syst Rev. 2011;16:CD006009.","journal-title":"Cochrane Database Syst Rev."},{"key":"329_CR17","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s13311-012-0139-4","volume":"9","author":"MJ Buchfuhrer","year":"2012","unstructured":"Buchfuhrer MJ. Strategies for the treatment of restless legs syndrome. Neurotherapeutics. 2012;9:776\u201390.","journal-title":"Neurotherapeutics."},{"key":"329_CR18","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1001\/archneur.61.9.1393","volume":"61","author":"W Ondo","year":"2004","unstructured":"Ondo W, Romanyshyn J, Vuong KD, et al. Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol. 2004;61:1393\u20137.","journal-title":"Arch Neurol"},{"key":"329_CR19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.sleep.2003.07.005","volume":"5","author":"JW Winkelman","year":"2004","unstructured":"Winkelman JW, Johnston L. Augmentation and tolerance with long-term prami-pexole treatment of restless legs syndrome (RLS). Sleep Med. 2004;5:9\u201314.","journal-title":"Sleep Med"},{"key":"329_CR20","first-page":"81","volume":"33","author":"JR Cornelius","year":"2010","unstructured":"Cornelius JR, Tippmann-Peikert M, Slocumb NL, et al. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep. 2010;33:81\u20137.","journal-title":"Sleep"},{"key":"329_CR21","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nrneurol.2015.122","volume":"11","author":"C Trenkwalder","year":"2015","unstructured":"Trenkwalder C, Winkelmann J, Inoue Y, et al. Restless legs syndrome-current therapies and management of augmentation. Nat Rev Neurol. 2015;11:434\u20135.","journal-title":"Nat Rev Neurol."},{"key":"329_CR22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2377-11-28","volume":"11","author":"D Garcia-Borreguero","year":"2011","unstructured":"Garcia-Borreguero D, Stillman P, Benes H, et al. Algorithms for the diagnosis and treatment of restless legs syndrome in primary care. BMC Neurol. 2011;11:28.","journal-title":"BMC Neurol."},{"key":"329_CR23","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.mayocp.2013.06.016","volume":"88","author":"MH Silber","year":"2013","unstructured":"Silber MH, Becker PM, Earley C, et al. Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome. Mayo Clin Proc. 2013;88:977\u201386.","journal-title":"Mayo Clin Proc"},{"key":"329_CR24","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1212\/01.wnl.0000341770.91926.cc","volume":"72","author":"CA Kushida","year":"2009","unstructured":"Kushida CA, Becker PM, Ellenbogen AL, et al. Randomized, double-blind, placebo-controlled study of XP13512\/GSK1838262 in patients with RLS. Neurology. 2009;72:439\u201346.","journal-title":"Neurology."},{"key":"329_CR25","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/jcm7090282","volume":"7","author":"DO Lee","year":"2011","unstructured":"Lee DO, Ziman RB, Perkins AT, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med. 2011;7:282\u201392.","journal-title":"J Clin Sleep Med"},{"key":"329_CR26","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/WNF.0b013e318259eac8","volume":"35","author":"R Lal","year":"2012","unstructured":"Lal R, Ellenbogen A, Chen D, et al. A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome. Clin Neuropharmacol. 2012;35:165\u201373.","journal-title":"Clin Neuropharmacol"},{"key":"329_CR27","unstructured":"HORIZANT\u00ae Prescribing Information and Medications Guides 2013, XenoPort, Inc., Santa Clara, CA. http:\/\/www.horizant.com . Accessed June 2015."},{"key":"329_CR28","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1124\/jpet.104.067959","volume":"311","author":"KC Cundy","year":"2004","unstructured":"Cundy KC, Annamalai T, Bu L, et al. XP13512 [(\u00b1)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther. 2004;311:324\u201333.","journal-title":"J Pharmacol Exp Ther"},{"key":"329_CR29","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1177\/0091270008322909","volume":"48","author":"KC Cundy","year":"2008","unstructured":"Cundy KC, Sastry S, Luo W, et al. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol. 2008;48:1378\u201388.","journal-title":"J Clin Pharmacol"},{"key":"329_CR30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/sleep\/32.2.159","volume":"32","author":"CA Kushida","year":"2009","unstructured":"Kushida CA, Walters AS, Becker P, et al. A randomized, double-blind, placebo-controlled, crossover study of XP13512\/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep. 2009;32:159\u201368.","journal-title":"Sleep"},{"key":"329_CR31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1185\/03007995.2012.746217","volume":"29","author":"Y Inoue","year":"2013","unstructured":"Inoue Y, Hirata K, Uchimura N, et al. Gabapentin enacarbil in Japanese patients with restless legs syndrome: a 12-week, randomized, double-blind, placebo-controlled, parallel-group study. Curr Med Res Opin. 2013;29:13\u201321.","journal-title":"Curr Med Res Opin"},{"key":"329_CR32","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3109\/07853890.2015.1025825","volume":"47","author":"RK Bogan","year":"2015","unstructured":"Bogan RK, Lee DO, Buchfuhrer MJ, et al. Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome: pooled analyses from 3 trials of gabapentin enacarbil. Ann Med. 2015;47:269\u201377.","journal-title":"Ann Med"},{"key":"329_CR33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/JPRLS.S40804","volume":"3","author":"RK Bogan","year":"2013","unstructured":"Bogan RK, Ellenbogen A, Becker PM. Gabapentin enacarbil in subjects with moderate to severe primary restless legs syndrome with and without severe sleep disturbance: an integrated analysis of subjective and novel sleep endpoints from two studies. J Parkinsonism Restl Legs Syndr. 2013;3:31\u201340.","journal-title":"J Parkinsonism Restl Legs Syndr"},{"key":"329_CR34","doi-asserted-by":"crossref","unstructured":"Hermanowicz N, Ellenbogen A, Irving G, et al. The effect of gabapentin enacarbil on pain associated with moderate-to-severe primary restless legs syndrome in adults: pooled analyses from 3 randomized controlled trials. CNS Drugs. 2016 (in press).","DOI":"10.1007\/s40263-016-0333-8"},{"key":"329_CR35","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1524-4733.2005.03010.x","volume":"8","author":"L Abetz","year":"2005","unstructured":"Abetz L, Vallow SM, Kirsch J, et al. Validation of the restless legs syndrome quality of life questionnaire. Value Health. 2005;8:157\u201367.","journal-title":"Value Health."},{"key":"329_CR36","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.5664\/jcsm.4300","volume":"10","author":"AS Walters","year":"2014","unstructured":"Walters AS, Frauscher B, Allen R, et al. Review of quality of life instruments for the restless legs syndrome\/Willis-Ekbom Disease (RLS\/WED): critique and recommendations. J Clin Sleep Med. 2014;10:1351\u20137.","journal-title":"J Clin Sleep Med"},{"key":"329_CR37","volume-title":"Manual for the profile of mood states","author":"DM McNair","year":"1992","unstructured":"McNair DM, Loor M, Droppleman LF. Manual for the profile of mood states. San Diego: Educational and Industrial Testing Service; 1992."},{"key":"329_CR38","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1389-9457(02)00258-7","volume":"4","author":"AS Walters","year":"2003","unstructured":"Walters AS, LeBrocq C, Dhar A, et al. Validation of the international restless legs syndrome study group rating scale for restless legs syndrome. Sleep Med. 2003;4:121\u201332.","journal-title":"Sleep Med"},{"key":"329_CR39","first-page":"294058","volume":"2012","author":"KE Innes","year":"2012","unstructured":"Innes KE, Selfe TK. The effects of a gentle yoga program on sleep, mood, and blood pressure in older women with restless legs syndrome (RLS): a preliminary randomized controlled trial. Evid Based Complement Alternat Med. 2012;2012:294058.","journal-title":"Evid Based Complement Alternat Med."},{"key":"329_CR40","first-page":"92","volume":"75","author":"C Trenkwalder","year":"2004","unstructured":"Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12\u00a0week, randomised, placebo-controlled study in 10 European countries. J Neurol Neurosurg Psychiatry. 2004;75:92\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"329_CR41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4065\/81.1.17","volume":"81","author":"RK Bogan","year":"2006","unstructured":"Bogan RK, Fry JM, Schmidt MH, et al. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc. 2006;81:17\u201327.","journal-title":"Mayo Clin Proc"},{"key":"329_CR42","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.sleep.2008.09.001","volume":"9","author":"L Ferini-Strambi","year":"2008","unstructured":"Ferini-Strambi L, Aarskog D, Partinen M, et al. Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial. Sleep Med. 2008;9:874\u201381.","journal-title":"Sleep Med"},{"key":"329_CR43","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-3-79","volume":"3","author":"L Abetz","year":"2005","unstructured":"Abetz L, Arbuckle R, Allen RP, et al. The reliability, validity and responsiveness of the restless legs syndrome quality of life questionnaire (RLSQoL) in a trial population. Health Qual Life Outcomes. 2005;3:79.","journal-title":"Health Qual Life Outcomes."},{"key":"329_CR44","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00415-005-0604-7","volume":"252","author":"J Winkelmann","year":"2005","unstructured":"Winkelmann J, Prager M, Lieb R, et al. \u201cAnxietas tibiarum\u201d. Depression and anxiety disorders in patients with restless legs syndrome. J Neurol. 2005;252:67\u201371.","journal-title":"J Neurol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0329-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-016-0329-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0329-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T16:55:01Z","timestamp":1600448101000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-016-0329-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["329"],"URL":"https:\/\/doi.org\/10.1007\/s40263-016-0329-4","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}